Arax Advisory Partners’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Arax Advisory Partners’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.6K	Buy	+210	New	+$11.5K	﹤0.01%	4189

Other funds holding SBIO

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

CIS

Connors Investor Services Wyomissing, Pennsylvania $1.16B AUM 27.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

MWM

Moran Wealth Management Naples, Florida $3.67B AUM 36.71% 1-Year Est. Return

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Arax Advisory Partners's SBIO Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in ALPS Medical Breakthroughs ETF (SBIO) in Q2 2026: 210 shares worth $13.6K. The stake represents ﹤0.01% of the portfolio and ranks #4189 among its holdings.

65 funds tracked by Wall St. Rank hold SBIO as of Q2 2026.

Arax Advisory Partners held 210 shares of ALPS Medical Breakthroughs ETF worth $13.6K as of Q2 2026.
ALPS Medical Breakthroughs ETF was a new Arax Advisory Partners position in Q2 2026.
ALPS Medical Breakthroughs ETF made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4189 holding.
65 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.